血浆生物标志物预测唐氏综合征患者脑内淀粉样蛋白与tau沉积及认知下降
这项纵向队列研究纳入258名≥25岁唐氏综合征成人,每16个月随访,评估血浆p-tau217、GFAP、Aβ42/40、NfL和t-tau与认知、Aβ-PET及tau-PET变化的关系。结果显示基线p-tau217独立关联认知下降、tau沉积和痴呆进展,基线p-tau217与GFAP共同关联Aβ沉积;纵向p-tau217和GFAP也显示类似关联。提示血浆p-tau217和GFAP可用于唐氏综合征相关阿尔茨海默病的预后评估。
要点
- 基线血浆p-tau217独立预测唐氏综合征患者认知下降、tau沉积和痴呆进展。
- 基线p-tau217和GFAP共同关联Aβ-PET变化,GFAP在联合模型中仍显著。
- 纵向p-tau217和GFAP变化与认知、tau及Aβ沉积变化相关。
核心结论
- 基线与纵向血浆p-tau217均与唐氏综合征患者后续整体认知下降、痴呆进展和tau负荷增加相关。
- 基线p-tau217和GFAP与Aβ积累相关,提示二者可用于该人群阿尔茨海默病预后评估。
研究设计与样本
- 纵向队列研究,纳入258名年龄≥25岁的唐氏综合征成人,来自美国与英国七个大学站点。
- 参与者每16个月前瞻性随访,基线及纵向评估血浆p-tau217、GFAP、Aβ42/40、NfL和t-tau。
- 采用线性回归分析生物标志物与DS-MSE、Aβ-PET及tau-PET变化的关系,Cox回归评估痴呆进展风险。
临床怎么用
- 血浆p-tau217和GFAP或可用于唐氏综合征成人阿尔茨海默病的预后评估与疾病进展监测。
- 研究结果支持在唐氏综合征相关阿尔茨海默病临床试验中评估这些生物标志物用于监测疾病进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Plasma biomarkers associated with Alzheimer's disease could improve prognostic assessment for people with Down syndrome in both clinical practice and research settings. We aimed to identify the plasma biomarkers that most accurately predict longitudinal changes in Alzheimer's disease-related pathology and cognitive functioning in individuals with Down syndrome. METHODS: This longitudinal cohort study included data from 258 adults (aged ≥25 years) with Down syndrome who were followed up prospectively every 16 months as part of the longitudinal Alzheimer's Biomarker Consortium-Down Syndrome study (recruited from seven university sites in the USA and UK between July 13, 2016, and Jan 15, 2019). Participants had baseline and longitudinal assessments of plasma tau phosphorylated at threonine 217 (p-tau217), glial fibrillary acidic protein (GFAP), amyloid β (Aβ)42/40, neurofilament light (NfL), or total tau (t-tau). Associations of baseline plasma biomarkers and longitudinal changes in plasma biomarkers with changes in global cognitive functioning (Down Syndrome Mental Status Examination [DS-MSE] scores), Aβ-PET, and tau-PET were examined using linear regression models. Plasma biomarker-associated risk of progression to dementia was assessed using Cox regression analysis. FINDINGS: Baseline p-tau217, as well as GFAP, NfL, or t-tau, were individually associated with longitudinal changes in DS-MSE, Aβ-PET, and tau-PET, and with progression to dementia. However, in combined models, only baseline p-tau217 remained associated with changes in DS-MSE (β -0·30 [95% CI -0·45 to -0·15], p=0·0001, n=220), tau-PET (0·42 [0·14 to 0·70], p=0·0039, n=88), and progression to dementia (hazard ratio 3·51 [95% CI 1·76-7·00], p=0·0004, n=194), whereas baseline p-tau217 (0·29 [0·14-0·45], p=0·0003) and GFAP (0·37 [0·18-0·56], p=0·0003) were associated with changes in Aβ-PET (n=106 for both). Similar associations were shown between longitudinal p-tau217 or GFAP and changes in DS-MSE (p-tau217: β -0·33 [95% CI-0·52 to -0·13], p=0·0015, n=133), tau-PET (p-tau217: 0·61 [0·40 to 0·83], p<0·0001, n=87), and Aβ-PET (p-tau217: 0·35 [0·19 to 0·50], p<0·0001; GFAP: 0·49 [0·27 to 0·70], p<0·0001, n=88). INTERPRETATION: Baseline and longitudinal plasma p-tau217 were associated with subsequent decline in global cognition, progression to dementia, and increased tau burden, whereas baseline p-tau217 and GFAP were associated with Aβ accumulation. These findings suggest that plasma p-tau217 and GFAP might be valuable for prognostic assessment of Alzheimer's disease in people with Down syndrome in both clinical and research contexts. The results further support evaluation of these biomarkers for monitoring disease progression in clinical trials of Down syndrome-related Alzheimer's disease. FUNDING: The European Research Council and National Institute on Aging (National Institute of Health).
引用
- Janelidze S, Collij LE, Mattsson-Carlgren N, et al. Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study. Lancet Neurol. 2025. PMID: 40541209. doi:10.1016/S1474-4422(25)00158-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。